Wearable Robotics Raises €5M for Rehab Tech Expansion

Italian innovator Wearable Robotics has successfully closed a €5 million Series A funding round, signaling a significant push to scale its advanced neuromotor rehabilitation robotics and exoskeleton technologies. This capital infusion is earmarked for accelerating global market penetration and enhancing product development, positioning the company for substantial growth in the rapidly expanding assistive technology sector.

The funding was spearheaded by CDP Venture Capital through its Accelerators Fund. Key strategic investors joining the round include MITO Technology (via its Tech Transfer fund), LIFTT, and SIMEST, utilizing resources from the F.394/81 Venture Capital and Participatory Investments Section in agreement with the Ministry of Foreign Affairs and International Cooperation. Further bolstering the syndicate are RoboIT, the National Technology Transfer Hub for Robotics and Industrial Automation, and the co-investment fund Toscana Next, managed by CDP Venture Capital and supported by prominent Tuscan foundations like Fondazione CR Firenze, Fondazione Cassa di Risparmio di Lucca, Fondazione Caript, and Fondazione Monte dei Paschi di Siena. This broad investor base underscores confidence in Wearable Robotics' potential within its specialized fields.

Founded in 2014 as a spin-off from the esteemed Scuola Superiore Sant’Anna, a leading research institution in wearable robotics, Wearable Robotics has established itself as a developer of high-efficiency robotic devices. The company's dual focus spans both medical rehabilitation and industrial applications. Its medical division, NEXUM Medical, concentrates on upper limb rehabilitation, integrating robotics with augmented and virtual reality (AR/VR) to enhance motor function recovery and support daily living activities. The industrial arm, NEXUM Industry, develops exoskeletons designed to mitigate worker fatigue and prevent musculoskeletal injuries during manual load handling.

Lucia Lencioni, CEO of Wearable Robotics, emphasized the strategic importance of this funding. "This round marks a pivotal moment in our journey," Lencioni stated. "We are laying the groundwork for sustainable, scalable expansion, while simultaneously investing in product innovation, regulatory compliance, and commercial outreach. Our objective is to deliver increasingly sophisticated and adaptable wearable robotic solutions that make a tangible difference across the entire rehabilitation spectrum."

The company's flagship product, ALEX RS, a bilateral upper limb neuromotor rehabilitation device, has already seen over 50 international installations, serving as a benchmark in rehabilitation robotics. The new capital will fuel the expansion of the product portfolio and bolster commercial development, aiming to solidify the company's competitive edge in key global markets, with a particular strategic focus on North America. Significant investment will also be directed towards navigating regulatory pathways in target markets, thereby expediting market entry and strengthening compliance.

The global market for assistive robotics is experiencing robust growth, driven by an aging population, increasing prevalence of neurological disorders, and a growing demand for solutions that enhance worker safety and productivity. Wearable Robotics is well-positioned to capitalize on these trends, leveraging its technological expertise and expanding international presence, which currently spans 20 countries. This Series A round provides the necessary resources to scale operations, enhance its product offerings, and capture a larger share of this dynamic market.